During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
News|Articles|July 3, 2026
Lung Cancer News Roundup: June 2026
Author(s)Targeted Oncology Staff
Fact checked by: Sabrina Serani
ASCO 2026 data reshapes lung cancer care, highlighting durable ALK control, new EGFR options, bispecific first-line gains, and SCLC progress.
Advertisement
Advertisement
Lung cancer news in June was dominated by ASCO 2026 readouts, with major movement in EGFR-mutated, ALK-positive, and small cell disease. Unlike breast cancer, lung cancer didn't see a wave of new FDA approvals this particular month—June's oncology approvals skewed toward breast, prostate, and bladder cancer—but several trials presented at ASCO are likely to drive approvals later this year. Here's what mattered.
Related to this article
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasive surgery.
In patients 45+ with papillary thyroid cancer, men with dual BRAF V600E and TERT promoter mutations face sharply higher mortality, reshaping risk stratification.
Advertisement
Advertisement